The combination of accelerating revenue growth, margin expansion, and a clear path to sustained profitability makes Omada an emerging leader in virtual chronic care. The strong cash position and positive free cash flow ($12.4M in 2025) reduce near-term dilution risk. Traders should monitor execution on 2026 guidance and member retention metrics.
Price Chart
Executive Summary
Omada Health reported strong fourth-quarter and full-year 2025 results with revenue up 58% YoY in Q4 to $75.8 million and 53% for the full year to $260.2 million. The company achieved positive net income of $5.2 million in Q4 and delivered full-year adjusted EBITDA of $6.5 million, a significant improvement from prior-year losses. It also raised 2026 revenue guidance to $312M–$322M, implying ~22% growth.
Key Financial Metrics
Key Facts
- Revenue was $75.8 million in Q4 2025, up 58% YoY; full-year revenue was $260.2 million, up 53% YoY
- Net income was $5.2 million in Q4 2025 vs. a $8.3 million loss in Q4 2024; full-year net loss narrowed to $12.8 million from $47.1 million
- Adjusted EBITDA was $8.5 million in Q4 and $6.5 million for the full year 2025, a turnaround from a $29.4 million loss in 2024
- Gross margin improved to 70.8% in Q4 (from 67.0% in Q4 2024) and 65.7% for the full year (from 60.6%)
- Cash and cash equivalents increased to $222.0 million from $76.4 million in 2024
- Company guided to 2026 revenue of $312M–$322M (midpoint $317M, +22% YoY) and adjusted EBITDA of $7M–$15M
Financial Impact
Revenue grew $90.4 million YoY to $260.2 million; net loss reduced by $34.4 million; adjusted EBITDA improved by $35.9 million; cash balance increased by $145.6 million
Risk Factors
- Forward-looking guidance excludes GAAP net loss reconciliation due to 'unreasonable effort,' limiting visibility into full profitability drivers
- Rapid growth may face headwinds from healthcare policy changes, payer contracting, or competition in the digital therapeutics space
- Related-party transactions are material (e.g., $49.5M in Q4 services revenue), raising potential conflict-of-interest considerations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Insider Cluster | $20.50 $20.61 | ▼ −0.54% | ▼ −0.43% | $20.65 (−0.73%) |
Sep 4, 2026 28d ago | Insider Cluster | $22.77 $20.50 | ▲ +9.97% | ▲ +8.76% | $20.65 (+9.31%) |
Sep 3, 2026 28d ago | Insider Cluster | $22.77 $20.50 | ▼ −9.97% | ▼ −8.76% | $20.65 (−9.31%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.84 $24.47 | ▲ +2.64% | ▲ +3.09% | $20.65 (−13.38%) |
Jul 23, 2026 10w ago | Press Release | $21.20 $19.69 | ▲ +7.12% | ▲ +7.60% | $20.65 (+2.59%) |
Jul 9, 2026 12w ago | Insider Cluster | $23.55 $23.67 | ▼ −0.51% | ▼ −0.64% | $20.65 (+12.31%) |
Jul 9, 2026 12w ago | Insider Cluster | $23.55 $23.67 | ▲ +0.51% | ▲ +0.64% | $20.65 (−12.31%) |
Jul 6, 2026 12w ago | Insider Cluster | $22.85 $23.28 | ▼ −1.88% | ▼ −1.39% | $20.65 (+9.63%) |
Jul 6, 2026 12w ago | Insider Cluster | $22.85 $23.28 | ▲ +1.88% | ▲ +1.39% | $20.65 (−9.63%) |
Jul 3, 2026 13w ago | Insider Cluster | $22.39 $23.55 | ▼ −5.18% | ▼ −4.25% | $20.65 (+7.77%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access